Oligomeric alpha-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson’s disease
Objective: To evaluate alterations in the phosphorylated, oligomeric alpha-synuclein and GBA activity levels in plasma from patients with sporadic Parkinson's disease (sPD), PD patients with…Vitamin D receptor polymorphisms and Parkinson’s disease in a Korean population: Revisited
Objective: We evaluated an association between PD and VDR polymorphisms including BsmI, FokI, ApaI, and TaqI and we also investigated the relationship between VDR polymorphisms…Transient parkinsonism during pregnancy in patient heterozygous for Gaucher’s disease: Case report
Objective: To present a case of a woman who became transient Parkinsonian during pregnancy and found to have a rare genetic mutation and describe response…Investigating voice as a biomarker of LRRK2-associated Parkinson’s disease (PD)
Objective: To test for an association between LRRK2 mutation and pathological changes in voice. Background: Voice impairment, characterized by reduced volume, breathiness, roughness and exaggerated…Systematic review of autosomal recessive parkinsonism using the MDGene database protocol
Objective: A systematic review of autosomal recessive parkinsonism using DJ-1 as an example. Background: MDGene is a genotype-phenotype database for rare mutations in movement disorders…A web resource on levodopa-induced dyskinesia (LID) genetics
Objective: Establish a web resource summarizing literature-based genetic information on levodopa-induced dyskinesia in an easily accessible and consistent way. Background: Levodopa induced dyskinesia (LID) is…Do mutations in the TGM6 (SCA35) gene cause early-onset Parkinson’s disease?
Objective: To identify the genetic cause of early-onset Parkinson's disease (EOPD) in a Serbian family. Background: Hereditary EOPD is a genetically heterogeneous neurodegenerative disorder, characterized…Effect of genetic variation in SNCA and APOE on cerebrospinal fluid protein levels in patients with Parkinson’s disease and controls
Objective: To determine whether genetic variability constitutes a source of heterogeneity in levels of cerebrospinal fluid (CSF) proteins in patients with Parkinson's disease (PD) and…Protective effects of ATP13A2 in Parkinson’s disease models
Objective: Decipher the role of ATP13A2 in Parkinson's disease. Background: ATP13A2 is a lysosomal P-type ATPase with significant implications in Parkinson's disease (PD). Little is…Gene network driven probable drug target identification: An in-silico study on Parkinson’s disease
Objective: Identification of probable drug targets. Background: Parkinson's disease, a motor system disorder, which manifests due to the loss of brain cells that produces dopamine.…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.